PURPOSE: We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count. METHODS: Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs). RESULTS: We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively). CONCLUSIONS: We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease. (c) 2006 Wiley-Liss, Inc.
PURPOSE: We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count. METHODS: Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs). RESULTS: We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively). CONCLUSIONS: We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease. (c) 2006 Wiley-Liss, Inc.
Authors: Scott M J Cornwall; Matthew Wikstrom; Arthur W Musk; John Alvarez; Anna K Nowak; Delia J Nelson Journal: Oncoimmunology Date: 2015-08-31 Impact factor: 8.110
Authors: Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz Journal: Prostate Date: 2010-03-01 Impact factor: 4.104
Authors: Vegard Tjomsland; Per Sandström; Anna Spångeus; Davorka Messmer; Johan Emilsson; Ursula Falkmer; Sture Falkmer; Karl-Eric Magnusson; Kurt Borch; Marie Larsson Journal: BMC Cancer Date: 2010-03-09 Impact factor: 4.430
Authors: Vegard Tjomsland; Anna Spångeus; Per Sandström; Kurt Borch; Davorka Messmer; Marie Larsson Journal: PLoS One Date: 2010-10-15 Impact factor: 3.240
Authors: Stefano Salciccia; Anna Laura Capriotti; Aldo Laganà; Stefano Fais; Mariantonia Logozzi; Ettore De Berardinis; Gian Maria Busetto; Giovanni Battista Di Pierro; Gian Piero Ricciuti; Francesco Del Giudice; Alessandro Sciarra; Peter R Carroll; Matthew R Cooperberg; Beatrice Sciarra; Martina Maggi Journal: Int J Mol Sci Date: 2021-04-22 Impact factor: 5.923
Authors: H van Cruijsen; K Hoekman; A G M Stam; A J M van den Eertwegh; B C Kuenen; R J Scheper; G Giaccone; T D de Gruijl Journal: Clin Dev Immunol Date: 2007